| Identification | Back Directory | [Name]
AMikacin (hydrate) | [CAS]
1257517-67-1 | [Synonyms]
D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy-α-D-glucopyranosyl-(1→4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-, hydrate (1:) | [EINECS(EC#)]
608-040-6 | [Molecular Formula]
C22H43N5O13.xH2O | [MDL Number]
MFCD11045969 | [MOL File]
1257517-67-1.mol | [Molecular Weight]
603.62 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Methanol (Slightly), Water (Sparingly) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Amikacin is an antibacterial compound used in the treatment of diseases and illnesses arising from gram-negative bacterium. Antituberculosis agent. | [Biological Activity]
Amikacin hydrate is an aminoglycoside antibiotic used to treat different types of bacterial infections. | [in vitro]
Amikacin is an aminoglycoside used to treat different types of bacterial infections. It acts by binding to the bacterial 30S ribosomal subunit, causing mistranslation of mRNA, thereby preventing the bacteria from synthesizing the proteins necessary for their growth. | [in vivo]
Amikacin (320?mg/kg; subcutaneous injection; daily; for 10 days; male Fischer rats) treatment increases the chance of serious hearing loss in rats in vivo[3]. | Animal Model: | Male Fischer 344 rats (40-50-day-old)[3] | | Dosage: | 320?mg/kg | | Administration: | Subcutaneous injection; daily; for 10 days | | Result: | Induced hearing loss in rats.
|
| [IC 50]
Aminoglycoside |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
|